A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study
Table 5
Exploratory Markers*.
Parameter
EZE + Statin
STAT2
-Value (Between-Group)**
Baseline
C-reactive Protein† (mg/L)
Mean ± SD
0.567
Median (Min; Max)
1.50 (0.00; 13.00)
2.00 (0; 27.00)
Interleukin-6† (pg/mL)
Mean ± SD
0.883
Median (Min; Max)
3.05 (1.00; 20.00)
2.92 (0.00; 9.00)
Apolipoprotein-B (g/L)
Mean ± SD
0.543
Median (Min; Max)
0.90 (0.57; 1.30)
0. 91 (0.61; 1.34)
Apolipoprotein-A1 (g/L)
Mean ± SD
0.780
Median (Min; Max)
1.43 (1.08; 1.89)
1.39 (0.85; 2.10)
ApoB/ApoA1
Mean ± SD
0.700
Median (Min; Max)
0.62 (0.33; 1.07)
0.62 (0.41; 1.00)
Adiponectin† (mg/L)
Mean ± SD
0.276
Median (Min; Max)
6.96 (3.89; 24.90)
7.82 (4.20; 16.59)
Leptin† (ng/mL)
Mean ± SD
26.96 ± 30.16
18.48 ± 13.14
0.623
Median (Min; Max)
17. 90 (2.00; 1.42)
13.97 (3.00; 46.00)
12 weeks mmol/L
C-reactive Protein† (mg/L)
Mean ± SD
0.079
Median (Min; Max)
1.10 (0.00; 16.00)
1.90 (0.00; 17.00)
Interleukin-6† (pg/mL)
Mean ± SD
0.306
Median (Min; Max)
3.08 (1.00; 5.00)
3.11 (1.00; 24.00)
Apolipoprotein-B† (g/L)
Mean ± SD
0.110
Median (Min; Max)
0.67 (0.44; 1.41)
0.79 (0.55; 1.06)
Apolipoprotein-A1 (g/L)
Mean ± SD
0.754
Median (Min; Max)
1.40 (1.07; 1.66)
1.42 (0.82; 1.98)
ApoB/ApoA1†
Mean ± SD
0.252
Median (Min; Max)
0.50 (0.30; 1.04)
0.55 (0.38; 1.05)
Adiponectin (mg/L)
Mean ± SD
0.638
Median (Min; Max)
7.35 (3.48; 17.42)
7.36 (3.99; 14.76)
Leptin† (ng/mL)
Mean ± SD
0.832
Median (Min; Max)
19.10 (3.00; 206.00)
21.40 (2.00; 65.00)
*Analysis performed on those patients with available data
**Mann-Whitney U non-parametric test for independent samples or independent samples t-test, depending on distribution assessed with Shapiro-Wilk test of normality. †For parameters not normally distributed, the median rather than the mean should be preferred.
